EGFR and non-small cell lung carcinoma: Recently, Tu et al., showed that in a xenograft mouse model of EGFR-mutated NSCLC, neither anti–PD-L1 nor anti-CD73 antibody alone inhibited tumor growth compared with the effect of the isotype control.